GlassScriptPhysician profile
Mark T Watkins
NPI 1336226166
$53,923.17
in general payments reported to CMS, 2019-2025
12 companies · $1,746 in 2025
The $1,746 reported for 2025 was more than what 92% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $5,358 · 2021: $1,860 · 2022: $11K · 2023: $5,343 · 2024: $1,815 · 2025: $1,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,961 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,900 · Education: $42.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,960.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,900.00 |
| Education | $42.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $30,195.62 | 2019-2025 | Descovy, Yeztugo, Epclusa |
| Viiv Healthcare Company | $21,113.09 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Merck Sharp & Dohme LLC | $771.64 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Janssen Biotech, INC. | $551.98 | 2019-2023 | Symtuza |
| Janssen Products, LP | $423.65 | 2019-2021 | |
| Theratechnologies INC. | $323.63 | 2020-2025 | Trogarzo, Egrifta |
| Lilly USA, LLC | $256.76 | 2023-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $200.53 | 2019-2024 | Ozempic |
| Abbvie INC. | $25.55 | 2025 | |
| Abbott Laboratories | $24.38 | 2021 | |
| Dexcom, INC. | $19.40 | 2023 | Dexcom G6 Transmitter |
| Emd Serono, INC. | $16.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.